AstraZeneca plc 22.9% Potential Decrease Indicated by UBS

Broker Ratings

AstraZeneca plc using EPIC/TICKER code (LON:AZN) had its stock rating noted as ‘Unchanged’ with the recommendation being set at ‘SELL’ today by analysts at UBS. AstraZeneca plc are listed in the Health Care sector within UK Main Market. UBS have set a target price of 5700 GBX on its stock. This would indicate that the analyst believes there is a downside of -22.9% from the opening price of 7392 GBX. Over the last 30 and 90 trading days the company share price has increased 1061 points and increased 1576 points respectively. The 1 year high for the stock price is 7475.15 GBX while the 52 week low for the share price is 5312 GBX.

AstraZeneca plc has a 50 day moving average of 6,632.04 GBX and a 200 Day Moving Average share price is recorded at 6,195.61. There are currently 1,311,876,336 shares in issue with the average daily volume traded being 2,198,374. Market capitalisation for LON:AZN is £96,009,278,905 GBP.

Share on:
Find more news, interviews, share price & company profile here for:
    AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases.
    AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials.
    AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival.

      Search

      Search